Glenmede Trust Co. NA raised its stake in Amdocs Limited (NASDAQ:DOX - Free Report) by 18.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 157,780 shares of the technology company's stock after buying an additional 24,442 shares during the period. Glenmede Trust Co. NA owned approximately 0.13% of Amdocs worth $13,803,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Pzena Investment Management LLC grew its position in Amdocs by 12.3% during the 3rd quarter. Pzena Investment Management LLC now owns 6,363,739 shares of the technology company's stock worth $556,700,000 after purchasing an additional 696,136 shares in the last quarter. LSV Asset Management grew its holdings in shares of Amdocs by 7.9% during the 2nd quarter. LSV Asset Management now owns 3,207,155 shares of the technology company's stock valued at $253,109,000 after acquiring an additional 234,096 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Amdocs by 36.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,175,790 shares of the technology company's stock valued at $277,818,000 after acquiring an additional 851,022 shares in the last quarter. Brandes Investment Partners LP grew its holdings in shares of Amdocs by 31.1% during the 2nd quarter. Brandes Investment Partners LP now owns 2,260,811 shares of the technology company's stock valued at $178,335,000 after acquiring an additional 536,359 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Amdocs by 39.5% during the 1st quarter. Vanguard Group Inc. now owns 2,033,536 shares of the technology company's stock valued at $183,771,000 after acquiring an additional 576,168 shares in the last quarter. Institutional investors own 92.02% of the company's stock.
Wall Street Analyst Weigh In
DOX has been the topic of several research analyst reports. StockNews.com cut shares of Amdocs from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 14th. Oppenheimer boosted their target price on shares of Amdocs from $98.00 to $105.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. Barclays cut their price objective on shares of Amdocs from $113.00 to $111.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th. Finally, Stifel Nicolaus started coverage on shares of Amdocs in a research report on Wednesday, October 2nd. They set a "buy" rating and a $100.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $101.83.
Read Our Latest Stock Analysis on DOX
Amdocs Price Performance
Shares of DOX traded down $0.46 during mid-day trading on Friday, hitting $86.72. 500,218 shares of the company traded hands, compared to its average volume of 681,238. Amdocs Limited has a one year low of $74.41 and a one year high of $94.04. The company has a current ratio of 1.20, a quick ratio of 1.24 and a debt-to-equity ratio of 0.21. The business has a 50-day moving average of $88.07 and a 200 day moving average of $84.05. The stock has a market capitalization of $10.19 billion, a price-to-earnings ratio of 20.45, a PEG ratio of 1.46 and a beta of 0.74.
Amdocs Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.479 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $1.92 annualized dividend and a yield of 2.21%. Amdocs's dividend payout ratio is currently 45.05%.
Amdocs Company Profile
(
Free Report)
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
Further Reading
Before you consider Amdocs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amdocs wasn't on the list.
While Amdocs currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
